Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

References

• OstlingSSkoogIPsychotic symptoms and paranoid ideation in a nondemented population-based sample of the very oldArch Gen Psychiatry2002591535911779282
   PubMed Web of Science ®Google Scholar
• JesteDVJLWCRDSchizophrenia and paranoid disordersBlazerDGSDBusseEWTextbook of Geriatric Psychiatry3rd edWashington, DCAmerian Psychiatric Publishing, Inc2004269281
   Google Scholar
• CummingsJLFBDDementia: A clinical approach2nd edBostonButterworth-Heinemann1992
   Google Scholar
• JesteDVFinkelSIPsychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndromeAm J Geriatr Psychiatry200081293410648292
   PubMed Web of Science ®Google Scholar
• BurnsAJacobyRLevyRPsychiatric phenomena in Alzheimer’s disease. IV: Disorders of behaviourBr J Psychiatry199015786942397368
   PubMed Web of Science ®Google Scholar
• FreedmanRSchizophreniaN Engl J Med2003349181738174914585943
   PubMed Web of Science ®Google Scholar
• WorrelJAMarkenPABeckmanSERuehterVLAtypical antipsychotic agents: a critical reviewAm J Health Syst Pharm200057323825510674777
   PubMed Web of Science ®Google Scholar
• CastleDJMurrayRMThe epidemiology of late-onset schizophreniaSchizophr Bull19931946917008303220
   PubMed Web of Science ®Google Scholar
• HowardRRabinsPVSeemanMVJesteDVLate-onset schizophrenia and very-late-onset schizophrenia-like psychosis: an international consensus. The International Late-Onset Schizophrenia GroupAm J Psychiatry2000157217217810671383
   PubMed Web of Science ®Google Scholar
• HowardRJGrahamCShamPA controlled family study of late-onset non-affective psychosis (late paraphrenia)Br J Psychiatry19971705115149330015
   PubMed Web of Science ®Google Scholar
• CopelandJRDeweyMEScottASchizophrenia and delusional disorder in older age: community prevalence, incidence, comorbidity, and outcomeSchizophr Bull19982411531619502553
   PubMed Web of Science ®Google Scholar
• KeithSJReigerDARaeDSSchizophrenic disorders in America: the epidemiologic catchment area studyNew YorkFree Press1991
   Google Scholar
• HuberGThe heterogeneous course of schizophreniaSchizophr Res19972823177185
   Web of Science ®Google Scholar
• BelitskyRMcGlashanTHThe manifestations of schizophrenia in late life: a dearth of dataSchizophr Bull19931946836858303218
   PubMed Web of Science ®Google Scholar
• RamRBrometEJEatonWWPatoCSchwartzJEThe natural course of schizophrenia: a review of first-admission studiesSchizophr Bull19921821852071621068
   PubMed Web of Science ®Google Scholar
• DavidsonMHarveyPDPowchikPSeverity of symptoms in chronically institutionalized geriatric schizophrenic patientsAm J Psychiatry199515221972077840352
   PubMed Web of Science ®Google Scholar
• HeatonRKGladsjoJAPalmerBWKuckJMarcotteTDJesteDVStability and course of neuropsychological deficits in schizophreniaArch Gen Psychiatry2001581243211146755
   PubMed Web of Science ®Google Scholar
• PalmerBWMcClureFSJesteDVSchizophrenia in late life: findings challenge traditional conceptsHarv Rev Psychiatry200192515811266402
   PubMed Web of Science ®Google Scholar
• MadhusoodananSShahPManagement of psychosis in patients with Alzheimer’s disease: focus on aripiprazoleClin Interv Aging20083349150118982919
   PubMed Web of Science ®Google Scholar
• PaulsenJSSalmonDPThalLJIncidence of and risk factors for hallucinations and delusions in patients with probable ADNeurology200054101965197110822438
   PubMed Web of Science ®Google Scholar
• RopackiSAJesteDVEpidemiology of and risk factors for psychosis of Alzheimer’s disease: a review of 55 studies published from 1990 to 2003Am J Psychiatry2005162112022203016263838
   PubMed Web of Science ®Google Scholar
• LopezOLWisniewskiSRBeckerJTBollerFDeKoskySTPsychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer diseaseArch Neurol199956101266127210520944
   PubMed Web of Science ®Google Scholar
• BriesacherBALimcangcoMRSimoni-WastilaLThe quality of antipsychotic drug prescribing in nursing homesArch Intern Med2005165111280128515956008
   PubMed Web of Science ®Google Scholar
• DewaCSRemingtonGHerrmannNFearnleyJGoeringPHow much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experienceClin Ther20022491466147612380638
   PubMed Web of Science ®Google Scholar
• AlexopoulosGSJSCarpenterDThe expert consensus guideline series: using antipsychotics in older patientsJ Clin Psychiatry200465Suppl 2
   Google Scholar
• WooltortonERisperidone (Risperdal): increased rate of cerebrovascular events in dementia trialsCMAJ2002167111269127012451085
   PubMed Web of Science ®Google Scholar
• WooltortonEOlanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trialsCMAJ20041709139515111472
   PubMed Web of Science ®Google Scholar
• Administration. FaD. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm Accessed November 3, 2005.
   Google Scholar
• MadhusoodananSShahPBrennerRGuptaSPharmacological treatment of the psychosis of Alzheimer’s disease: what is the best approach?CNS Drugs200721210111517284093
   PubMed Web of Science ®Google Scholar
• SajatovicMCoconceaNIgnacioRVAripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trialJ Clin Psychiatry2008691414618312036
   PubMed Web of Science ®Google Scholar
• HirschfeldRMCalabreseJRWeissmanMMScreening for bipolar disorder in the communityJ Clin Psychiatry2003641535912590624
   PubMed Web of Science ®Google Scholar
• GildengersAGMulsantBHBegleyAEA pilot study of standardized treatment in geriatric bipolar disorderAm J Geriatr Psychiatry200513431932315845758
   PubMed Web of Science ®Google Scholar
• FriedmanJHFactorSAAtypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s diseaseMov Disord200015220121110752567
   PubMed Web of Science ®Google Scholar
• Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. The Parkinson Study GroupN Engl J Med19993401075776310072410
   PubMed Web of Science ®Google Scholar
• BruceMLTen HaveTRReynoldsCF3rdReducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trialJAMA200429191081109114996777
   PubMed Web of Science ®Google Scholar
• UnutzerJKatonWCallahanCMCollaborative care management of late-life depression in the primary care setting: a randomized controlled trialJAMA2002288222836284512472325
   PubMed Web of Science ®Google Scholar
• PapakostasGISheltonRCSmithJFavaMAugmentation of anti-depressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysisJ Clin Psychiatry200768682683117592905
   PubMed Web of Science ®Google Scholar
• BermanRMMarcusRNSwaninkRThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768684385317592907
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther2002302138138912065741
   PubMed Web of Science ®Google Scholar
• DeLeonAPatelNCCrismonMLAripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerabilityClin Ther200426564966615220010
   PubMed Web of Science ®Google Scholar
• Ltd OPCProduct information: ABILIFY(R) oral tablets, oral solution, IM injection, ABILIFY DISCMELT(R) orally disintegrating tables, aripiprazole oral tablets, oral solution, IM injection, orally disintegrating tabletsTokyo, Japan; 2009
   Google Scholar
• BoultonDWKolliaGMallikaarjunSPharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophreniaClin Pharmacokinet200847747548518563956
   PubMed Web of Science ®Google Scholar
• WaadeRBChristensenHRudbergIRefsumHHermannMInfluence of comedication on serum concentrations of aripiprazole and dehydroaripiprazoleTher Drug Monit200931223323819142178
   PubMed Web of Science ®Google Scholar
• CitromeLMacherJPSalazarDEMallikaarjunSBoultonDWPharmacokinetics of aripiprazole and concomitant carbamazepineJ Clin Psychopharmacol200727327928317502775
   PubMed Web of Science ®Google Scholar
• MallikaarjunSShoafSEBoultonDWBramerSLEffects of hepatic or renal impairment on the pharmacokinetics of aripiprazoleClin Pharmacokinet200847853354218611062
   PubMed Web of Science ®Google Scholar
• ColeyKCScipioTMRubyCLenzeEJFabianTJAripiprazole prescribing patterns and side effects in elderly psychiatric inpatientsJ Psychiatr Pract200915215015319339850
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
   PubMed Web of Science ®Google Scholar
• MortimerAMSymptom rating scales and outcome in schizophreniaBr J Psychiatry Suppl200750s7s1418019038
   PubMedGoogle Scholar
• KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry200263976377112363115
   PubMed Web of Science ®Google Scholar
• McEvoyJPDanielDGCarsonWHJrMcQuadeRDMarcusRNA randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophreniaJ Psychiatr Res2007411189590517631314
   PubMed Web of Science ®Google Scholar
• PotkinSGSahaARKujawaMJAripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderArch Gen Psychiatry200360768169012860772
   PubMed Web of Science ®Google Scholar
• CutlerAJMarcusRNHardySAO’DonnellACarsonWHMcQuadeRDThe efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophreniaCNS Spectr2006119691702 quiz 719.16946694
   PubMed Web of Science ®Google Scholar
• PigottTACarsonWHSahaARTorbeynsAFStockEGIngenitoGGAripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week studyJ Clin Psychiatry20036491048105614628980
   PubMed Web of Science ®Google Scholar
• [package insert] Ap. Otsuka America Pharmaceutical, Inc., Rockville MD and Bristol-Myers Squibb Co., Princeton NJ; November 2002.
   Google Scholar
• MadhusoodananSBrennerRGuptaSReddyHBogunovicOClinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studiesCNS Spectr200491186286715520608
   PubMed Web of Science ®Google Scholar
• De DeynPJesteDVSwaninkRAripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: a randomized, placebo-controlled studyJ Clin Psychopharmacol200525546346716160622
   PubMed Web of Science ®Google Scholar
• StreimJEBrederCSwaninkRFlexible dose aripiprazole in psychosis of Alzheimer’s dementia (poster)Presented at the 157th American Psychiatric Association Meeting2004
   Google Scholar
• MintzerJETuneLEBrederCDAripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed dosesAm J Geriatr Psychiatry2007151191893117974864
   PubMed Web of Science ®Google Scholar
• FriedmanJHBermanRMGoetzCGOpen-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson‘s diseaseMov Disord200621122078208117013906
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcQuadeRDA randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorderJ Clin Psychiatry200667462663716669728
   PubMed Web of Science ®Google Scholar
• KeckPEJrMarcusRTourkodimitrisSA placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar maniaAm J Psychiatry200316091651165812944341
   PubMed Web of Science ®Google Scholar
• SachsGSanchezRMarcusRAripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyJ Psychopharmacol200620453654616401666
   PubMed Web of Science ®Google Scholar
• YoungRCBiggsJTZieglerVEMeyerDAA rating scale for mania: reliability, validity and sensitivityBr J Psychiatry1978133429435728692
   PubMed Web of Science ®Google Scholar
• HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196023566214399272
   PubMed Web of Science ®Google Scholar
• AndrezinaRJosiassenRCMarcusRNIntramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidolPsychopharmacology (Berl)2006188328129216953381
   PubMed Web of Science ®Google Scholar
• Tran-JohnsonTKSackDAMarcusRNAubyPMcQuadeRDOrenDAEfficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trialJ Clin Psychiatry200768111111917284138
   PubMed Web of Science ®Google Scholar
• RutherfordBSneedJMiyazakiMAn open trial of aripiprazole augmentation for SSRI non-remitters with late-life depressionInt J Geriatr Psychiatry2007221098699117340654
   PubMed Web of Science ®Google Scholar
• SheffrinMDriscollHCLenzeEJPilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remissionJ Clin Psychiatry200970220821319210951
   PubMed Web of Science ®Google Scholar
• PetrieJLSahaARMcEvoyJPAripiprazole, a new atypical antipsychotic: Phase 2 clinical trial resultsEur Neuropsychopharmacol19977Suppl 2S227
   Google Scholar
• DanielDGSahaARIngenitoGAripiprazole: a novel antipsychotic: Overview of phase II study resultsInt J Neuropsychopharmacol20003Suppl 1S157
   Google Scholar
• MarderSRMcQuadeRDStockEAripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsSchizophr Res2003612–312313612729864
   PubMed Web of Science ®Google Scholar
• HildrumBMykletunAHoleTMidthjellKDahlAAAge-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 studyBMC Public Health2007722017727697
   PubMed Web of Science ®Google Scholar
• McQuadeRDStockEMarcusRA comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind studyJ Clin Psychiatry200465Suppl 18475615600384
   PubMed Web of Science ®Google Scholar
• De HertMHanssensLvan WinkelRA case series: evaluation of the metabolic safety of aripiprazoleSchizophr Bull200733382383016940338
   PubMed Web of Science ®Google Scholar
• NewcomerJWCamposJAMarcusRNA multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapineJ Clin Psychiatry20086971046105618605811
   PubMed Web of Science ®Google Scholar
• Quality of life compendiuCenter for Quality of Life Research in Nursing Science Section for Nursing Science, Department of Public Health and Primary Health Care, University of BergenURL: http://www.uib.no/isf/people/doc/qol/httoc.htm Accessed August 28, 2009.
   Google Scholar
• HanssensLL’ItalienGLozeJYMarcusRNPansMKerselaersWThe effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)BMC Psychiatry200889519102734
   PubMed Web of Science ®Google Scholar
• TaylorDHanssensLLozeJYPansML’ItalienGMarcusRNPreference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR studyEur Psychiatry200823533634318423987
   PubMed Web of Science ®Google Scholar
• KasperSLermanMNMcQuadeRDEfficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophreniaInt J Neuropsychopharmacol20036432533714609439
   PubMed Web of Science ®Google Scholar
• McGavinJKGoaKLAripiprazoleCNS Drugs20021611779786 discussion 787–778.12383035
   PubMed Web of Science ®Google Scholar
• CaseyDECarsonWHSahaARSwitching patients to aripiprazole from other antipsychotic agents: a multicenter randomized studyPsychopharmacology (Berl)2003166439139912610718
   PubMed Web of Science ®Google Scholar
• El-SayehHGMorgantiCAripiprazole for schizophreniaCochrane Database Syst Rev20062CD00457816625607
   PubMed Web of Science ®Google Scholar
• KasperSResingerECognitive effects and antipsychotic treatmentPsychoneuroendocrinology200328Suppl 1273812504070
   PubMed Web of Science ®Google Scholar
• LublinHEberhardJLevanderSCurrent therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychoticsInt Clin Psychopharmacol200520418319815933479
   PubMed Web of Science ®Google Scholar
• KernRSGreenMFCornblattBAThe neurocognitive effects of aripiprazole: an open-label comparison with olanzapinePsychopharmacology (Berl)2006187331232016810506
   PubMed Web of Science ®Google Scholar
• CaseyDEMetabolic issues and cardiovascular disease in patients with psychiatric disordersAm J Med2005118Suppl 215S22S15903291
   PubMedGoogle Scholar
• BassonBRKinonBJTaylorCCSzymanskiKAGilmoreJATollefsonGDFactors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidoneJ Clin Psychiatry200162423123811379836
   PubMed Web of Science ®Google Scholar
• StreetJSClarkWSGannonKSOlanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study GroupArch Gen Psychiatry2000571096897611015815
   PubMed Web of Science ®Google Scholar
• ParkSParkHTogoFYear-long physical activity and metabolic syndrome in older Japanese adults: cross-sectional data from the Nakanojo StudyJ Gerontol A Biol Sci Med Sci200863101119112318948564
   PubMed Web of Science ®Google Scholar
• StewartKJBacherACTurnerKExercise and risk factors associated with metabolic syndrome in older adultsAm J Prev Med2005128191815626550
   PubMed Web of Science ®Google Scholar
• SolomonDKPortnerTSBassGEClinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes studyJ Am Pharm Assoc (Wash)19983855745859782691
   PubMedGoogle Scholar
• SchoenMDDiDomenicoRJConnorSEDischlerJEBaumanJLImpact of the cost of prescription drugs on clinical outcomes in indigent patients with heart diseasePharmacotherapy200121121455146311765297
   PubMed Web of Science ®Google Scholar
• MaguraSLaudetABMahmoodDRosenblumAKnightEAdherence to medication regimens and participation in dual-focus self-help groupsPsychiatr Serv200253331031611875225
   PubMed Web of Science ®Google Scholar
• KellyGRScottJEMamonJMedication compliance and health education among outpatients with chronic mental disordersMed Care19902812118111972250501
   PubMed Web of Science ®Google Scholar
• CorrissDJSmithTEHullJWLimRWPrattSIRomanelliSInteractive risk factors for treatment adherence in a chronic psychotic disorders populationPsychiatry Res199989326927410708273
   PubMed Web of Science ®Google Scholar
• WeidenPJOlfsonMCost of relapse in schizophreniaSchizophr Bull19952134194297481573
   PubMed Web of Science ®Google Scholar
• GreenJHFrequent rehospitalization and noncompliance with treatmentHosp Community Psychiatry19883999639663215645
   PubMedGoogle Scholar
• OlfsonMMechanicDHansellSBoyerCAWalkupJWeidenPJPredicting medication noncompliance after hospital discharge among patients with schizophreniaPsychiatr Serv200051221622210655006
   PubMed Web of Science ®Google Scholar
• SunSXLiuGGChristensenDBFuAZReview and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United StatesCurr Med Res Opin200723102305231217697454
   PubMed Web of Science ®Google Scholar
• JesteDVBlazerDCaseyDACNP White Paper: update on use of antipsychotic drugs in elderly per sons with dementiaNeuropsychopharmacology200833595797017637610
   PubMed Web of Science ®Google Scholar
• CrismonMLArgoTRBuckleyPFSchizophreniaDiPiroJTTalbertRLYeeGCPharmacotherapy: A Pathophysiologic Approach7th edNew YorkMcGraw-Hill200810991123
   Google Scholar